Objective: To evaluate the incremental economic and clinical burden among patients with chronic inflammatory demyelinating polyneuropathy (CIDP) in the United States (US) compared to matched controls without CIDP.
Methods: This retrospective cohort study was conducted using Optum Market Clarity data from January 2016 – December 2023. CIDP patients were selected based on: (1) ≥2 claims with CIDP, ≥30-≤365 days apart (first claim is index), (2) ≥1 nerve conduction test ≤90 days before or after index, with ≥1 CIDP claim following it within 365 days, (3) continuous enrollment 1 year pre- and 2 years post-index date. CIDP patients were 1:3 propensity score (PS)-matched to controls without CIDP. Outcomes, including all-cause healthcare resource utilization (HCRU) and costs, and clinical characteristics over the two-year follow-up period were compared between cohorts using generalized linear models.
Results: Among 1,435 CIDP patients and 4,305 controls, CIDP patients had over 3x greater mean all-cause healthcare costs over a two-year follow-up period ($170,275 vs. $49,486; p<0.001), primarily driven by prescription and drug administration cost ($93,126 vs. $11,529; p<0.001). CIDP cohort also had more HCRU across all care settings, with outpatient care being the largest contributor. CIDP patients more frequently utilized CIDP-specific treatments like steroids (62% vs. 43%), immunoglobulins (54% vs 0%) and other medications including anti-convulsants (58% vs. 20%), opioids (53% vs. 38%) and anti-depressants (48% vs. 30%) relative to controls (all p<0.0001) over the follow-up. CIDP patients also had a higher comorbidity burden during follow-up, with increased prevalence of neuropathic pain (100% vs 41%), back pain (71% vs. 45%), osteoarthritis (54% vs 47%), sleep disorders (46% vs 33%), peripheral vascular disease (34% vs 24%) and cerebrovascular disease (29% vs 18%). Conclusions: Based on US claims data, CIDP has a substantial incremental economic and clinical burden compared to matched controls without CIDP.